What is the stage of development of EBV-001?

EBV-001 is in the preclinical development stage. We have collected data on safety and efficacy of the vaccine candidate in animal studies and we plan to produce the first batch of  product for human use in 2025 with clinical trials starting in due course.
 

Is EBV-001 safe?

Based on all information available and our own preclinical data, we are convinced that EBV-001 is a safe product for vaccinees. 

When will EBV-001 be available to the public?

We have to perform several stages of clinical trials (phase I to III) prior to applying for a marketing authorization. In a best case scenario, we will enter the market in several years. 

I am suffering from an EBV-associated disease (e.g. chronic fatigue syndrome, EBV-positive solid tumors). Is there a way to participate in clinical trials or otherwise obtain EBV-001 earlier?

We are very conscious of the high unmet medical need and suffering of those affected by an EBV-associated disease. Initially, the vaccine will be developed to prevent Infectious Mononucleosis (IM) and its sequelae (ME/CFS) in individuals who have not encountered the virus in their childhood or adolescence. These individuals are at high risk to develop IM after first contact and infection with EBV. 

Can EBV-001 help treating my Long-COVID symptoms?

There is no clear evidence that EBV is the causative agent for Long-COVID. Thus, we do not plan to develop EBV-001 for this indication.